Adults with persistent acne — breakouts that continue past the teen years — can rank three hormonal options by strength of proof. Spironolactone leads for select adult women, metformin helps mainly as an add-on, and bicalutamide remains investigational. Androgens are hormones that raise oil production and drive many adult breakouts. This review explains what each drug does, who may benefit, and what safety checks to discuss with a dermatologist.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What does spironolactone offer adult women?
- When does metformin help acne?
- Why is bicalutamide still investigational for acne?
- How can adults compare risks and next steps?
What does spironolactone offer adult women?
Spironolactone blocks androgen receptors and lowers sebum, the oil that clogs pores. The American Academy of Dermatology conditionally recommends it off-label for acne in select adult women, according to the AAD guideline summary. In the SAFA phase-3 trial, 410 adult women with persistent acne took spironolactone or placebo. Those on spironolactone reported greater acne improvement at 12 and 24 weeks.
Quality of life also improved, as reported by the University of Southampton and NIHR in its trial summary. Dermatology studies typically use 50-200 mg daily, with response over about 3 months. The DailyMed label from the U.S. National Library of Medicine warns it can raise potassium. It bars use with high potassium, absent urine output, or kidney impairment.
When does metformin help acne?
Metformin helps acne mainly as added therapy in polycystic ovary syndrome and insulin-resistant adults. In one randomized study, 850 mg daily added to tetracycline plus benzoyl peroxide lowered acne severity scores more than antibiotics alone.
UC Davis reported the result in the Dermatology Online Journal study. The FDA-approved metformin label reproduced by NDC List carries a boxed warning for rare but potentially fatal lactic acidosis. Gut upset is common at start, so later new gut symptoms need medical review rather than assumed tolerance.
Why is bicalutamide still investigational for acne?
Bicalutamide is an FDA-approved selective androgen-receptor blocker for metastatic prostate cancer. Dermatologists have studied it off-label at about 10-50 mg daily for hair loss, oily skin, acne and excess hair in women, as described in a Journal of the American Academy of Dermatology research letter. Acne evidence comes only from small pilot, retrospective and hair-loss groups, not large acne trials.
An Indian Dermatology Online Journal review of 17- to 44-patient series calls it investigational and notes pregnancy prevention plus liver checks in practice. The FDA Casodex label reports hepatitis or sharp liver-enzyme rises leading to stoppage in about 1% of trial patients. It also lists postmarketing deaths or hospital stays from severe liver injury, usually in the first 3-4 months, per the FDA prescribing information.
How can adults compare risks and next steps?
Comparison turns on proof, fit, and monitoring burden. Spironolactone fits select adult women with persistent breakouts. Metformin fits those with polycystic ovary syndrome or insulin resistance as an add-on.
Bicalutamide fits only closely monitored off-label care. Use this list to prepare for the visit: Bring all current drugs and supplements to that visit. Do not start, stop, or combine hormone-acting drugs without direct medical guidance.
- note breakout pattern, duration, and prior antibiotic or benzoyl peroxide use
- list potassium, kidney, gut, liver, and pregnancy issues
- ask what labs and follow-up each option needs
You Might Also Like
- Limited Topical Spironolactone Evidence in the 2026 Review: How Adults With Persistent Acne Can Compare Treatment Options
- Adult Female Acne Antiandrogen Treatments in a 2026 Review: How Adults With Persistent Acne Can Compare Treatment Options
- Topical Clascoterone Evidence Revisited in 2026: How Adults With Persistent Acne Can Compare Treatment Options